1 May 2024 - Boehringer Ingelheim announced today that the US FDA has approved the high concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company's interchangeable biosimilar to Humira (adalimumab), to treat multiple chronic inflammatory diseases.

The high concentration formulation (100 mg/mL), which is now available as a pre-filled syringe or pre-filled auto-injector, is priced at a 5% discount to Humira under the brand name Cyltezo and at an 81% discount to Humira as the unbranded product adalimumab-adbm.

Read Boehringer Ingelheim press release